PCIB.OL

PCI Biotech Holding ASA [PCIB.OL] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

PCIB.OL Stock Summary

In the News

PCIB.OL Financial details

Company Rating
-
Market Cap
66.44M
Income
-26.14M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
6
Optionable
No
Shortable
Yes
Earnings
10 May 2024
P/E
-3.03
Forward P/E
-
PEG
0.59
P/S
-
P/B
1.81
P/C
-
P/FCF
-2.51
Quick Ratio
8.49
Current Ratio
9.69
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.7
EPS next Y
-
EPS next Q
-
EPS this Y
-62.5%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
53.33%
-
-
-
-
SMA20
-
SMA50
-12.5%
SMA100
-36.36%
Inst Own
-
Inst Trans
-
ROA
-53%
ROE
-51%
ROC
-0.65%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.2-3.4
52W High
-93.97%
52W Low
-81.9%
RSI
46.2
Rel Volume
7.02
Avg Volume
90.31K
Volume
633.69K
Perf Week
-23.95%
Perf Month
-6.46%
Perf Quarter
-43.61%
Perf Half Y
-55.2%
-
-
-
-
Beta
1.615
-
-
Volatility
0.02%, 0.04%
Prev Close
0.56%
Price
0.181
Change
-8.12%

Something similar

Top by Market Cap
FXAIX
GOOGL
TL0.DE
BRK-B
TSLA
Same Sector
OKDBV.HE
DRMAW
005500.KS
ESSI
VRPX
Same Price Range
1703.HK
AFAGR.HE
SBSAA
GLGI
NEXT.TO
Similar Market Cap
NANO.L
RYCVX
MDUNDO.CO
1326.HK
HNW

Company Profile

Healthcare Biotechnology
  • Volume Average 90.31K
  • Market Capitalization 66.44M
  • Employee 6
  • CEO Mr. Ronny Skuggedal
  • Headquarters Oslo,NO
  • IPO Date 2008-06-23
  • Website https://www.pcibiotech.com

PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization (PCI) technology platform. The company develops anticancer paradigms, including fimaCHEM, a chemotherapeutics for treatment of cancer; fimaVACC, a T-cell induction technology for therapeutic vaccination, which is in Phase I clinical study; and fimaNAc, a nucleic acid therapeutics delivery technology, which is in pre-clinical study. It also offers Amphinex, a photosensitiser fimaporfin. The company has collaborative research programs with Bavarian Nordic, BioNTech, Phio Pharmaceuticals, DCprime, eTheRNA immunotherapies, IMV, and Aposense. PCI Biotech Holding ASA is based in Oslo, Norway.